Recent studies have identified GP73 as a potential novel serum marker of cancer, including hepatocellular carcinomas (HCC) [4,5], lung cancer [6] and prostate cancer [7], and as an independent prognostic factor for tumor recurrence and poor overall survival [8]. This evidence concerns the gene GOLM1 and cancer.